"Integrin alphaXbeta2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A major adhesion-associated heterodimer molecule expressed by MONOCYTES; GRANULOCYTES; NK CELLS; and some LYMPHOCYTES. The alpha subunit is the CD11C ANTIGEN, a surface antigen expressed on some myeloid cells. The beta subunit is the CD18 ANTIGEN.
| Descriptor ID |
D016167
|
| MeSH Number(s) |
D12.776.395.550.200.275 D12.776.543.550.200.275 D12.776.543.750.705.408.600.100 D12.776.543.750.705.833.249 D23.050.301.350.275
|
| Concept/Terms |
Integrin alphaXbeta2- Integrin alphaXbeta2
- alphaXbeta2, Integrin
- Complement Receptor Type 4
- CR4 Receptor
- Leukocyte Adhesion Protein p150,95
- Neutrophil Glycoprotein Gp150
- Glycoprotein Gp150, Neutrophil
- Gp150, Neutrophil Glycoprotein
- Antigen p150,95
- p150,95 Antigen
- Antigen, p150,95
- p150,95 Glycoprotein
- Glycoprotein, p150,95
- Receptor, CR4
- alphaXbeta2 Integrin
- Integrin, alphaXbeta2
- Complement Receptor 4
- Neutrophil GP150
- GP150, Neutrophil
|
Below are MeSH descriptors whose meaning is more general than "Integrin alphaXbeta2".
Below are MeSH descriptors whose meaning is more specific than "Integrin alphaXbeta2".
This graph shows the total number of publications written about "Integrin alphaXbeta2" by people in this website by year, and whether "Integrin alphaXbeta2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Integrin alphaXbeta2" by people in Profiles.
-
In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity. 2002 Aug; 17(2):211-20.
-
Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity. J Immunother. 2002 May-Jun; 25(3):269-77.